Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors

Clinical Cancer Research

Volumn 14, Issue 4, 2008, Pages 1116-1123

  Pardo, Beatriz ^a   Paz Ares, Luis ^c   Tabernero, Josep ^b   Ciruelos, Eva ^c   García, Margarita ^a   Salazar, Ramón ^b   López, Ana ^c   Blanco, María ^d   Nieto, Antonio ^d   Jimeno, José ^d   Izquierdo, Miguel Ángel ^a   Trigo, José Manuel ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; FORMESTANE; GEMCITABINE; IFOSFAMIDE; KAHALALIDE F; METHOTREXATE; NAVELBINE; PACLITAXEL; RECOMBINANT ALPHA2B INTERFERON; TAMOXIFEN; THIOTEPA;

ABNORMAL SENSATION; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; EYELID PRURITUS; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMORRHOID; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LUNG ADENOCARCINOMA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SENSE OF OPPRESSION; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; SPAIN; STEADY STATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 39749173071     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4366     Document Type: Article

References (17)

1. Hamann MT, Scheuer PJ. Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc 1993;115:5825-6.
2. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp.(1). J Org Chem 1996;61:6594-600.
3. Lopez-Macia A, Jimenez JC, Royo M, Giralt E, Albericio F. Synthesis and structure determination of kahalalide F (1,2). J Am Chem Soc 2001;123:11398-401.
4. Faircloth GT, Smith B, Grant W, et al. Selective antitumor activity of Kahalalide F, a marine-derived cyclic depsipeptide. Proc Am Assoc Cancer Res 2001;42:213.
5. Hanauske AR, Hanauske U, Von Hoff DD. The human tumor clonogenic assay in cancer research and therapy. Curr Probl Cancer 1985;9:1-66.
6. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2003;2:863-72.
7. Faircloth G, Cuevas C. Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 2006;43:363-79.
8. Garcia-Rocha M, Bonay P, Avila J. The antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett 1996;99:43-50.
9. Wosikowski K, Schuurhuis D, Johnson K, et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997;89:1505-15.
10. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA, Giaccone G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol 2005;68:502-10.
11. Brown AP, Morrissey RL, Faircloth GT, Levine BS. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat. Cancer Chemother Pharmacol 2002;50:333-40.
12. Rademaker-Lakhai JM, Horenblas S, Meinhardt W, et al. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 2005;11:1854-62.
13. Stokvis E, Rosing H, Lopez-Lazaro L, et al. Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry. J Mass Spectrom 2002;37:992-1000.
14. Stokvis E, Rosing H, Lopez-Lazaro L, Schellens JH, Beijnen JH. Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance. Biomed Chromatogr 2004;18:400-2.
15. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-83.
16. Sparidans RW, Stokvis E, Jimeno JM, Lopez-Lazaro L, Schellens JH, Beijnen JH. Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anticancer Drugs 2001;12:575-82.
17. Jimeno J, Lopez-Martin JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004;15:321-9.